To include your compound in the COVID-19 Resource Center, submit it here.

Kiadis: The meaning in mixtures

In the target-rich post-genomics era, medicinal chemistry, target validation and toxicology remain bottlenecks in drug development. Kiadis B.V. has developed a technology for looking at complex mixtures that it says can address these key steps.

The company's technology enables decisions to be made about molecules by improving on older separation methods used to search for active compounds in complex mixtures. Indeed, the technology encourages the creation of even more complex mixtures in order to find molecules

Read the full 756 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers